28322271|t|Mechanistic and structural basis of bioengineered bovine Cathelicidin-5 with optimized therapeutic activity
28322271|a|Peptide - drug discovery using host-defense peptides becomes promising against antibiotic - resistant pathogens and cancer cells. Here, we customized the therapeutic activity of bovine cathelicidin-5 targeting to bacteria, protozoa, and tumor cells. The membrane dependent conformational adaptability and plasticity of cathelicidin-5 is revealed by biophysical analysis and atomistic simulations over 200 Î¼s in thymocytes, leukemia, and E. coli cell-membranes. Our understanding of energy - dependent cathelicidin-5 intrusion in heterogeneous membranes aided in designing novel loss/gain-of-function analogues. In vitro findings identified leucine-zipper to phenylalanine substitution in cathelicidin-5 (1-18) significantly enhance the antimicrobial and anticancer activity with trivial hemolytic activity. Targeted mutants of cathelicidin-5 at kink region and N-terminal truncation revealed loss-of-function. We ensured the existence of a bimodal mechanism of peptide action (membranolytic and non-membranolytic) in vitro. The melanoma mouse model in vivo study further supports the in vitro findings. This is the first structural report on cathelicidin-5 and our findings revealed potent therapeutic application of designed cathelicidin-5 analogues.
28322271	16	26	structural	T082	UMLS:C0678594
28322271	36	49	bioengineered	T091	UMLS:C0005539
28322271	50	56	bovine	T204	UMLS:C3667982
28322271	57	71	Cathelicidin-5	T103	UMLS:C0671062
28322271	87	107	therapeutic activity	T058	UMLS:C0556489
28322271	108	115	Peptide	T103	UMLS:C0030956
28322271	118	132	drug discovery	T062	UMLS:C0920472
28322271	139	151	host-defense	T038	UMLS:C0520990
28322271	152	160	peptides	T103	UMLS:C0030956
28322271	187	197	antibiotic	T103	UMLS:C0003232
28322271	224	236	cancer cells	T017	UMLS:C0334227
28322271	262	282	therapeutic activity	T058	UMLS:C0556489
28322271	286	292	bovine	T204	UMLS:C3667982
28322271	293	307	cathelicidin-5	T103	UMLS:C0671062
28322271	321	329	bacteria	T007	UMLS:C0004611
28322271	331	339	protozoa	T204	UMLS:C0033739
28322271	345	356	tumor cells	T017	UMLS:C0597032
28322271	362	370	membrane	T017	UMLS:C0596901
28322271	381	395	conformational	T082	UMLS:C0026377
28322271	427	441	cathelicidin-5	T103	UMLS:C0671062
28322271	457	468	biophysical	T091	UMLS:C0005553
28322271	469	477	analysis	T062	UMLS:C0936012
28322271	482	503	atomistic simulations	T062	UMLS:C0679083
28322271	519	529	thymocytes	T017	UMLS:C0814999
28322271	531	539	leukemia	T038	UMLS:C0023418
28322271	545	552	E. coli	T007	UMLS:C0014834
28322271	553	567	cell-membranes	T017	UMLS:C0007603
28322271	609	623	cathelicidin-5	T103	UMLS:C0671062
28322271	624	633	intrusion	T058	UMLS:C0087111
28322271	651	660	membranes	T017	UMLS:C0007603
28322271	686	707	loss/gain-of-function	T033	UMLS:C0243095
28322271	708	717	analogues	T103	UMLS:C0002776
28322271	748	762	leucine-zipper	T103	UMLS:C0079686
28322271	766	779	phenylalanine	T103	UMLS:C0031453
28322271	796	810	cathelicidin-5	T103	UMLS:C0671062
28322271	844	857	antimicrobial	T038	UMLS:C1321418
28322271	862	881	anticancer activity	T033	UMLS:C0243095
28322271	895	913	hemolytic activity	T033	UMLS:C2945560
28322271	915	931	Targeted mutants	T038	UMLS:C0596988
28322271	935	949	cathelicidin-5	T103	UMLS:C0671062
28322271	969	990	N-terminal truncation	T038	UMLS:C1514568
28322271	1000	1016	loss-of-function	T033	UMLS:C0243095
28322271	1069	1076	peptide	T103	UMLS:C0030956
28322271	1085	1098	membranolytic	T033	UMLS:C2825141
28322271	1103	1120	non-membranolytic	T033	UMLS:C2825141
28322271	1136	1144	melanoma	T038	UMLS:C0025202
28322271	1145	1156	mouse model	T038	UMLS:C2986594
28322271	1250	1264	cathelicidin-5	T103	UMLS:C0671062
28322271	1298	1321	therapeutic application	T058	UMLS:C0278296
28322271	1334	1348	cathelicidin-5	T103	UMLS:C0671062
28322271	1349	1358	analogues	T103	UMLS:C0002776